Nippon Life Global Investors Americas Inc. Boosts Position in CVS Health Corporation $CVS

by · The Markets Daily

Nippon Life Global Investors Americas Inc. raised its stake in CVS Health Corporation (NYSE:CVS – Free Report) by 22.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 89,250 shares of the pharmacy operator’s stock after purchasing an additional 16,650 shares during the period. Nippon Life Global Investors Americas Inc.’s holdings in CVS Health were worth $6,729,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Avion Wealth lifted its position in CVS Health by 99.0% in the second quarter. Avion Wealth now owns 380 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 189 shares during the last quarter. Harbor Capital Advisors Inc. lifted its holdings in shares of CVS Health by 72.1% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock valued at $26,000 after purchasing an additional 142 shares during the last quarter. Corundum Trust Company INC acquired a new stake in shares of CVS Health in the 3rd quarter valued at about $29,000. Harbor Asset Planning Inc. purchased a new position in CVS Health during the 2nd quarter worth approximately $30,000. Finally, Front Row Advisors LLC increased its position in CVS Health by 436.5% during the second quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock worth $31,000 after buying an additional 371 shares during the period. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Stock Down 3.5%

CVS stock opened at $78.51 on Friday. The company has a current ratio of 0.83, a quick ratio of 0.63 and a debt-to-equity ratio of 0.83. The company’s 50-day moving average price is $78.84 and its 200 day moving average price is $74.29. CVS Health Corporation has a 52 week low of $51.79 and a 52 week high of $85.15. The company has a market cap of $99.66 billion, a P/E ratio of 206.61, a P/E/G ratio of 0.72 and a beta of 0.48.

CVS Health (NYSE:CVS – Get Free Report) last posted its quarterly earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.36 by $0.24. The company had revenue of $102.87 billion during the quarter, compared to the consensus estimate of $98.85 billion. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period last year, the firm earned $1.09 EPS. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. On average, research analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd will be issued a $0.665 dividend. The ex-dividend date of this dividend is Thursday, January 22nd. This represents a $2.66 annualized dividend and a yield of 3.4%. CVS Health’s dividend payout ratio is 700.00%.

Analysts Set New Price Targets

Several research firms have recently weighed in on CVS. Leerink Partners increased their price objective on CVS Health from $86.00 to $95.00 and gave the company an “outperform” rating in a report on Thursday, October 16th. Evercore ISI increased their price target on shares of CVS Health from $85.00 to $95.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. Piper Sandler reaffirmed an “overweight” rating and issued a $101.00 target price (up from $99.00) on shares of CVS Health in a report on Wednesday, December 10th. Truist Financial set a $100.00 price target on CVS Health in a report on Wednesday, December 10th. Finally, Jefferies Financial Group boosted their price target on CVS Health from $92.00 to $98.00 in a research report on Thursday, October 30th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.86.

Read Our Latest Stock Report on CVS Health

CVS Health Company Profile

(Free Report)

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Read More

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS – Free Report).